secwatch.observer — SEC 8-K summary
======================================

Issuer:     INVIVO THERAPEUTICS HOLDINGS CORP. (—)
CIK:        0001292519
Form:       8-K
Filed at:   2023-12-01T23:59:59+00:00
Accession:  0001104659-23-122862
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

InVivo Therapeutics receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period until May 29, 2024
--------------------------------------------------------------------------------

- Company's common stock bid price closed below $1.00 per share for 30 consecutive business days.
- Initial 180-day compliance period ends May 29, 2024; must close at $1.00+ for 10 consecutive days.
- If compliance not achieved, Nasdaq may delist; company can appeal to Listing Qualifications Panel.
- Company may be eligible for an additional 180-day cure period if it meets other listing standards.
- Options considered include monitoring bid price and potential reverse stock split to regain compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1292519/000110465923122862/0001104659-23-122862-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1292519/000110465923122862/tm2332011d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-122862

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer